{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:05:14Z","timestamp":1791813914518,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"NEI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.oret.2024.03.014","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:45:53Z","timestamp":1710981953000},"page":"733-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab"],"prefix":"10.1016","volume":"8","author":[{"given":"Cindy X.","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-2513","authenticated-orcid":false,"given":"Akihiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-7730","authenticated-orcid":false,"given":"Mary G.","family":"Bowring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6228-6000","authenticated-orcid":false,"given":"Erik","family":"Westlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2886-6984","authenticated-orcid":false,"given":"Diep","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia H.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4883-3099","authenticated-orcid":false,"given":"Jody-Ann","family":"McLeggon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-3865","authenticated-orcid":false,"given":"Scott L.","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-4147","authenticated-orcid":false,"given":"Michael E.","family":"Matheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-155X","authenticated-orcid":false,"given":"Asieh","family":"Golozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-6682","authenticated-orcid":false,"given":"Anna","family":"Ostropolets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Minty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3697-1477","authenticated-orcid":false,"given":"Fan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9612-5697","authenticated-orcid":false,"given":"Brian","family":"Toy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1724-1858","authenticated-orcid":false,"given":"Michelle","family":"Hribar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-1394","authenticated-orcid":false,"given":"Thomas","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lawrence-Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-7095","authenticated-orcid":false,"given":"Michael V.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-7704","authenticated-orcid":false,"given":"Kerry","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-1819","authenticated-orcid":false,"given":"Nathan","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Shoaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Reps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-5347","authenticated-orcid":false,"given":"Anthony G.","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-2124","authenticated-orcid":false,"given":"Clair","family":"Blacketer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-2737","authenticated-orcid":false,"given":"Joel","family":"Swerdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-4383","authenticated-orcid":false,"given":"Zachary","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Zeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-5776","authenticated-orcid":false,"given":"Deidra C.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-479X","authenticated-orcid":false,"given":"Marc A.","family":"Suchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-7614","authenticated-orcid":false,"given":"George","family":"Hripcsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2024.03.014_bib1","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2024.03.014_bib2","doi-asserted-by":"crossref","first-page":"xli","DOI":"10.1016\/j.ajo.2017.12.019","article-title":"Evolution of intravitreal therapy for retinal diseases-from CMV to CNV: the LXXIV Edward Jackson memorial lecture","volume":"191","author":"Martin","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.03.014_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence","volume":"96","author":"Hanna","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.oret.2024.03.014_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.oret.2024.03.014_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.oret.2024.03.014_bib6","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","article-title":"Proteinuria and the risk of developing end-stage renal disease","volume":"63","author":"Iseki","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.oret.2024.03.014_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Relation between kidney function, proteinuria, and adverse outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2024.03.014_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamainternmed.2019.6390","article-title":"Post-acute kidney injury proteinuria and subsequent kidney disease progression: the Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study","volume":"180","author":"Hsu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.oret.2024.03.014_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1100397","article-title":"Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study","volume":"10","author":"Jiang","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.oret.2024.03.014_bib10","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systematic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.03.014_bib11","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2024.03.014_bib12","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ckj\/sfab066","article-title":"Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration","volume":"14","author":"Phadke","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.oret.2024.03.014_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaophthalmol.2023.2098","article-title":"Systemic adverse events among patients with diabetes treated with intravitreal anti-vascular endothelial growth factor injections","volume":"141","author":"Zafar","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2024.03.014_bib14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/jdi.12771","article-title":"Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease","volume":"9","author":"Kameda","year":"2018","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.oret.2024.03.014_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12882-019-1650-1","article-title":"Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease","volume":"20","author":"O\u2019Neill","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.oret.2024.03.014_bib16","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/ndt\/gfac305","article-title":"A\u00a0systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes","volume":"38","author":"Lees","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.oret.2024.03.014_bib17","doi-asserted-by":"crossref","unstructured":"Tsao YC, Chen TY, Wang LA, et\u00a0al. Acute kidney injury from intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized controlled trials. BioDrugs;37:843\u2013854.","DOI":"10.1007\/s40259-023-00621-6"},{"key":"10.1016\/j.oret.2024.03.014_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ckj\/sfy060","article-title":"Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension","volume":"12","author":"Hanna","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.oret.2024.03.014_bib19","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2024.03.014_bib20","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.17-22853","article-title":"Changes in blood pressure and urine albumin-creatine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic maculara edema","volume":"59","author":"Glassman","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2024.03.014_bib21","first-page":"574","article-title":"Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers","volume":"216","author":"Hripcsak","year":"2015","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.oret.2024.03.014_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","article-title":"Validation of a common data model for active safety surveillance research","volume":"19","author":"Overhage","year":"2012","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1016\/j.oret.2024.03.014_bib25","first-page":"826","article-title":"Phenotyping in distributed data networks: selecting the right codes for the right patients","volume":"2022","author":"Ostropolets","year":"2022","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.oret.2024.03.014_bib26","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ophtha.2011.09.058","article-title":"Rationale for the Diabetic Retinopathy Clinical Research network treatment protocol for center-involved diabetic macular edema","volume":"118","author":"Aiello","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.03.014_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.oret.2024.03.014_bib28","first-page":"1","article-title":"KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.oret.2024.03.014_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103363","article-title":"Adapting electronic health records-derived phenotypes to claims data: lessons learned in using limited clinical data for phenotyping","volume":"102","author":"Ostropolets","year":"2020","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.oret.2024.03.014_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103258","article-title":"PheValuator: development and evaluation of a phenotype algorithm evaluator","volume":"97","author":"Swerdel","year":"2019","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.oret.2024.03.014_bib33","doi-asserted-by":"crossref","DOI":"10.1145\/2414416.2414791","article-title":"Massive parallelization of serial inference algorithms for a complex generalized linear model","volume":"23","author":"Suchard","year":"2013","journal-title":"ACM Trans Model Comput Simul"},{"key":"10.1016\/j.oret.2024.03.014_bib35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","article-title":"Diabetes Complications Severity Index (DCSI)-update and ICD-10 translation","volume":"31","author":"Glasheen","year":"2017","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.oret.2024.03.014_bib36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.oret.2024.03.014_bib37","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.oret.2024.03.014_bib40","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","article-title":"Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis","volume":"394","author":"Suchard","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2024.03.014_bib41","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/ije\/dyy120","article-title":"Evaluating large-scale propensity score performance through real-world and synthetic data experiments","volume":"47","author":"Tian","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.oret.2024.03.014_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2022.104204","article-title":"Adjusting for indirectly measured confounding using large-scale propensity score","volume":"134","author":"Zhang","year":"2022","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.oret.2024.03.014_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/09622802211060518","article-title":"Combining cox regressions across a heterogeneous distributed research network facing small and zero counts","volume":"31","author":"Schuemie","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.oret.2024.03.014_bib46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.ki.5002343","article-title":"Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes","volume":"72","author":"Levey","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.oret.2024.03.014_bib47","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2024.03.014_bib48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3928\/23258160-20210330-05","article-title":"Racial differences in anti-VEGF intravitreal injections among commercially insured beneficiaries","volume":"52","author":"Al-Moujahed","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.03.014_bib49","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.oret.2018.05.005","article-title":"Racial differences in age-related macular degeneration and associated anti-vascular endothelial growth factor intravitreal injections among Medicare beneficiaries","volume":"2","author":"Mahr","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2024.03.014_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2024.03.014_bib51","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"6","author":"Virgili","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2024.03.014_bib52","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2023.2307","article-title":"Difficulty in assessing the systemic adverse effects of intravitreal anti-vascular endothelial growth factor therapy","volume":"141","author":"VanderBeek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2024.03.014_bib53","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s40264-017-0581-7","article-title":"Channeling in the use of nonprescription paracetamol and ibuprofen in an electronic medical records database: evidence and implications","volume":"40","author":"Weinstein","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.oret.2024.03.014_bib54","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40264-020-00950-3","article-title":"Channeling bias in the analysis of risk of myocardial infarction, stroke, gastrointestinal bleeding, and acute renal failure with the use of paracetamol compared with ibuprofen","volume":"43","author":"Weinstein","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.oret.2024.03.014_bib55","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1073\/pnas.1708282114","article-title":"Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data","volume":"115","author":"Schuemie","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.oret.2024.03.014_bib56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T11:50:28Z","timestamp":1733917828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653024001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2468653024001180"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2024.03.014","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}